AtaiBeckley Inc.

Good morning, and welcome to the Atai Life Sciences third quarter 2021 financial results and corporate update conference call. Currently, all participants are in a listen-only mode. This call is being webcast live via the news and events section of the company's website at www.atai.life, and it is being recorded. For opening remarks, I would like to introduce Chad Messer, Vice President of Investor Relations and Strategic Finance of Atai Life Sciences. Please go ahead.

Thank you. Welcome, everyone, to the third quarter 2021 Atai Life Sciences Corporate Update Conference Call. The press release reporting our financial results is available in the Investors and Media section of our website, www.atai.life, and our quarterly report on Form 10-Q, ended September 30th, 2021, will be filed today with the SEC. Joining me today are Florian Brand, our co-founder and chief executive officer, Dr. Srinivas Rao, our co-founder and chief scientific officer, and Greg Weaver, our chief financial officer. During today's call, we will be making certain forward-looking statements that are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements represent management's current expectations and projections about future results and performance as of today, the TIE's results are subject to many risks and uncertainties that could cause results to differ materially from those expectations. In addition to any risks highlighted during this call, these statements are subject to additional risks described in our filings made with the Securities and Exchange Commission including our final prospectus filed with the SEC on September 30, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, November 15, 2021, and, except as required by law, a TIE disclaims any obligation to update such statements. I would now like to turn the call over to a TIE CEO, Florian Brand. Florian?

Good morning and thank you all for joining our 2021 third quarter earnings call today. To begin, I will provide a few introductory comments and reiterate the strategy underpinning our vision to heal mental health disorders so that everyone everywhere can live a more fulfilled life. Then my co-founder and CISO Srini will review highlights from our drug development pipeline. And finally, our CFO Greg will provide the quarterly financial report followed by the Q&A. Building on the momentum of our successful IPO on NASDAQ in June, we have continued to advance our innovative and diversified pipeline focused on differentiated approaches to address important unmet patient needs in mental health. In addition, we anticipate further growing our drug development pipeline and enabling technologies through a buy and build approach and will remain highly active in business development. In response to the heterogeneous mental health patient population, we plan to tailor our treatments to individual patient needs by using a diverse set of biomarkers supported by digital therapeutics and robust insights from our multimodal data approach. Just last week, we were excited to see strong, positive Phase IIb data from Compass Pathways, the very first company that we funded to research the therapeutic potential of psychedelics. This clinical trial investigated Compass' proprietary formulation of psilocybin, COM-360. It demonstrated rapid onset of effects and durability in treatment-resistant depression. In a few minutes, Srini will provide further details on these important results. Later this year, we anticipate another top-line data readout of our Phase IIa biomarker study with RL007 in cognitive impairment associated with schizophrenia, or CIAS. We were encouraged by the interim data readout earlier this quarter. and we are eagerly anticipating the full results of the study, given the lack of progress in developing treatments for CIAS, which still has no approved treatments. As for our discovery stage assets, earlier this quarter, we announced the launch of Cyprotix, a precision psychiatry company focused on developing therapeutics for mental health indications. Cyprotix will study metabolic mechanisms associated with depression symptoms with a goal of deriving more tailored treatments to better meet individual patient needs. We expect to launch clinical trials in 2023. We have also seen great progress on our enabling technologies. For example, in NRS-Bio, which is developing a Sol-gel-based excipient technology to effectively transport compounds directly from the nose to the brain, recently completed a preclinical proof of principle study. We anticipate applying this technology across various drug candidates in our pipeline. In September, our company Introspect launched a user acceptability study of our digital therapeutic app in patients with treatment-resistant depression undergoing ketamine therapy. In addition, our BCI company, Cyber, will soon begin testing a virtual reality and neurofeedback-based proof-of-concept device to support the in-clinic patient experience. We are currently optimizing the device ahead of inclusion in the clinical trials of Viridia, EmpathBio, Revixia, and Demorex IB. We are making great progress towards our goal of a broad pipeline of novel, transformative mental health therapies tailored to patient needs. I will now hand over to Srini to take us through some of our key pipeline updates and upcoming milestones. Srini?